Syntekabio, a pioneer in artificial intelligence-driven drug development, is poised to make waves at the BioTechX USA conference in Philadelphia, PA, from September 17-18, 2024. As the Title Sponsor, the company will spotlight its AI solutions that are setting new benchmarks in the pharmaceutical industry. This event marks a pivotal moment for AI in drug discovery, with Syntekabio leading the charge in integrating these technologies to streamline research and development processes.
Dr. Jongsun Jung, CEO of Syntekabio, shared his excitement about the conference, emphasizing the company's eagerness to engage with potential clients and explore how their AI-driven technologies can revolutionize R&D activities. A standout feature of their presentation is the 'Develop Now, Pay Later' initiative, a novel business model designed to eliminate financial hurdles in early-stage drug discovery by allowing clients to validate target proteins without upfront costs.
The conference will also feature a keynote by Dr. Jonathan Witztum, CTO of Syntekabio USA, addressing the challenge of data scarcity in drug discovery through physics-based AI models. Dr. Jung will further elaborate on Syntekabio's advancements in biologics discovery, including their innovative platforms, Neo-ARS™ and Ab-ARS™, which are at the forefront of personalized neoantigen cancer vaccines and novel antibody drug prediction.
With access to over 10 billion known compounds and 1,400 drug targets, Syntekabio's AI Bio-Supercom Center is a testament to the company's commitment to leveraging technology for drug discovery. This infrastructure supports their mission to accelerate the development of targeted therapeutics, offering hope for more effective treatments in personalized medicine and oncology.
Syntekabio's showcase at BioTechX USA is not just a demonstration of their technological capabilities but a beacon for the future of drug development. By harnessing the power of AI, the company is contributing to a paradigm shift in how new treatments are discovered and developed, promising a faster, more efficient, and cost-effective pathway to bringing life-saving drugs to market.
